Application of IL-33 in preparation of medicine for regulating proportion and quantity of ILC2 cells
Through IL-33, the regulation of ILC2 cells and ST2+ immune cells and combined with PD-1 antibodies solves the problem of poor activation of single immune cells, significantly improves the tumor immune microenvironment, and realizes the coordinated anti-tumor of multiple immune cells, which is better than the existing ones Immune checkpoint inhibitors have universal anti-tumor effects.
Patent Information
- Application Number
- CN202310625722.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-05-30
AI Technical Summary
In the prior art, the application effect of a single preparation to activate a certain type of immune cell in tumors is not ideal, and tumor immunosuppression microenvironment leads to drug resistance, making it difficult to effectively mobilize the synergy of various immune cells in the body to improve the anti-tumor effect.
IL-33 regulates the proportion and number of ILC2 cells, promotes its antigen presentation function, activates T cells, and increases tumor infiltration of ST2+ immune cells to synergistically exert antitumor effects, and uses in combination with PD-1 antibodies to enhance antitumor activity.
IL-33 significantly increases the number and proportion of tumor-infiltrated immune cells, improves the immune microenvironment, is better than existing immune checkpoint inhibitors, has universal anti-tumor effects, and can be used as a vaccine enhancer to enhance the prevention and treatment of tumors.
Smart Images

Figure CN119055748A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicine, and in particular to the use of IL-33 in the preparation of drugs for regulating the proportion and number of ILC2 cells and enhancing the effect of tumor vaccines. Background Art
[0002] Cancer is a major disease that threatens human health. Although treatment methods are becoming more and more abundant, the treatment effect is minimal. As a new force in the field of tumor treatment, immunotherapy has made breakthrough progress in the clinical treatment of many types of cancer. The most representative ones are immune checkpoint inhibitors (such as PD-1 and PD-L1 antibodies) and CAR-T cell therapy. With the continuous accumulation of clinical data, the results show that although this targeted immunotherapy has a strong potential for treating tumors, its beneficiaries are limited, and the complex inhibitory tumor microenvironment leads to drug resistance from time to time. More and more evidence shows that the application effect of a single agent to activate a certain type of immune cell in solid tumors is not ideal. For example, in CAR-T cell therapy, although T cells have the characteristics of specific tumor killing through genetic engineering, the existence of tumor immunosuppressive microenvironment makes it difficult for CAR-T to play a good anti-tumor effect in solid tumors. Therefore, fully mobilizing the synergistic effect of various immune cells in the body and improving the inhibitory immune microenvironment to an immune-promoting immune microenvironment is a new direction for tumor immunotherapy.
[0003] IL-33 belongs to the IL-1 family and is mainly expressed in epithelial cells, fibroblasts and endothelial cells. It is a multifunctional cytokine that participates in the pathogenesis of many diseases and has important biological functions in the development and regulation of immune cells, the maintenance, repair and reconstruction of tissue homeostasis. Under normal circumstances, IL-33 exists in the cell nucleus. When cells are damaged, IL-33 will be released as an alarmin, prompting the body to clear damaged cells. It serves as a key self-stabilizing regulator of immune cells such as ILC2 in various tissues including but not limited to the small intestine, lungs, adipose tissue and skin.
[0004] In existing studies, the role of IL-33 in tumors is still controversial, and both tumor-promoting and tumor-suppressing effects have been reported. In terms of tumor promotion, IL-33 can act as an effector of chromatin activation, cooperating with KRAS mutation to induce carcinogenesis and tumor transformation of early pancreatic cancer. IL-33 can also specifically regulate tumor-infiltrating suppressive immune cells to promote tumor development. For example, studies have found that Treg in tumors endogenously express IL-33, which plays an important role in Treg suppressing immune responses and promoting tumor progression. IL-33 gene knockout significantly increases the expression of NF-κB-T-bet-dependent IFNγ in Treg cells, thereby reducing their immunosuppressive function. IL-9 secreted by ILC2 can activate Treg cells through the interaction of GITR-GITRL and ICOS-ICOSL, thereby promoting Treg-mediated immunosuppression. IL-33-activated ILC2 can secrete IL-13, thereby activating M-MDSC (monocytic myeloid-derived suppressor cells) to promote the development of acute myeloid leukemia. In the lungs, IL-33 can promote the activation of ILC2 in the lungs to inhibit NK cell-mediated natural anti-tumor immunity and promote lung metastasis of tumors. The tumor-promoting effect of IL-33 on ILC2 is related to peroxisome proliferator-activated receptor gamma (PPARγ). Blocking or deleting PPARγ can significantly inhibit the tumor-promoting effect caused by IL-33 stimulating ILC2 to secrete cytokines. In terms of tumor suppression, Hollande et al. showed that tumor-derived IL-33 can increase the secretion of CCL11 in tumors, induce eosinophil infiltration and degranulation to mediate eosinophil-dependent anti-tumor immune activity. IL-33 can also activate tumor ILC2 and CD8 + T cells, inhibiting the development of pancreatic cancer in situ. By further combining with the immune checkpoint inhibitor PD-1 antibody, the inhibitory effect of intrinsically expressed PD-1 on the anti-tumor activity of ILC2 can be effectively alleviated, thereby enhancing the anti-tumor activity and promoting the anti-tumor effect of primary pancreatic ductal adenocarcinoma. The granulocyte-macrophage colony stimulating factor (GM-CSF) expressed by ILC2 can recruit and activate eosinophils to synergistically exert anti-tumor immune activity. Therefore, the effect of IL-33 on tumors may depend on factors such as tumor type and the composition of immune cells in the tumor microenvironment.
[0005] The combined IL-33 and PD-1 inhibitor antibodies reported in 2021 can significantly increase the anti-tumor activity of ILC2. The document shows that the anti-tumor effect of IL-33 and PD-1 antibodies alone is minimal, and the anti-tumor activity is significantly enhanced when the two are used in combination. Although the combination of the two can change the proportion and number of tumor-infiltrating immune cells, there is no significant enhancement of the anti-tumor effect. There are also patents that mention that the administration of an effective amount of IL-33 or an agonist or antagonist of the receptor complex (IL-33R) is suitable for regulating immune disorders including cancer. IL-33 is used as an agonist or one of the compositions, and the content of the cancer involved in the patent only involves the expression of IL-33 in the tumor itself. There is no experimental data to support that exogenous administration of IL-33 can inhibit tumors, and it only shows that after seven days of intraperitoneal injection of IL-33 into normal WT mice, IL-33 can significantly increase the number of white blood cells in the blood of mice, but it does not involve the effect of IL-33 on tumor-infiltrating lymphocytes. Therefore, it is not yet known how IL-33 regulates tumor-infiltrating lymphocytes to exert tumor immune responses. Summary of the invention
[0006] In view of the defects in the prior art, the present invention proposes the use of IL-33 in the preparation of drugs for regulating the proportion and number of ILC2 cells and enhancing the effect of tumor vaccines.
[0007] The present invention provides the use of IL-33 in the preparation of a drug for regulating the proportion and number of ILC2 cells.
[0008] Furthermore, the proportion and / or number of ILC2 cells increases.
[0009] Furthermore, the dosage of IL-33 is 0.5-1 μg / mouse / day, preferably 0.5 μg / mouse / day or 1 μg / mouse / day.
[0010] Furthermore, the IL-33 is administered daily 2 days in advance, intermittently 1 day in advance, simultaneously, or when a tumor visible to the naked eye grows.
[0011] Furthermore, IL-33 acts synergistically by promoting the antigen presentation function of ILC2 cells to activate T cells and increase the tumor infiltration of ST2-expressing immune cells.
[0012] Furthermore, the drug is an immune activator or a vaccine enhancer, and the vaccine is any one of an mRNA vaccine, a DC vaccine, and a dead cell vaccine.
[0013] The present invention also provides the use of IL-33 in preparing a drug for treating cancer, wherein the cancer is any one of colon cancer, breast cancer, lung cancer and melanoma.
[0014] The present invention also provides the use of IL-33 in the preparation of a drug for enhancing the preventive and / or anti-tumor effects of tumor vaccines.
[0015] Furthermore, the tumor vaccine is any one of mRNA vaccine, DC vaccine or dead cell vaccine.
[0016] Furthermore, the drug increases the proportion and / or number of ILC2 cells.
[0017] Furthermore, the tumor is any one of colon cancer, breast cancer, lung cancer and melanoma.
[0018] In summary, compared with the prior art, the present invention achieves the following technical effects:
[0019] IL-33 has both preventive and therapeutic effects on the occurrence and development of tumors. IL-33 can act as an immune activator to mobilize the body's immune cells expressing ST2, such as ILC2 cells, ST2 + The tumor infiltration of Treg cells and eosinophils synergistically prevents and hinders the growth of tumors. Compared with existing CAR-T cell therapies that can only mobilize a single type of immune cells to exert anti-tumor activity, it can mobilize multiple immune cells to exert anti-tumor activity; the anti-tumor effect is universal. And by comparing the therapeutic effects of IL-33 and existing PD-1 and CTLA-4 antibodies at the same time, IL-33 activates multiple immune cells to synergistically exert anti-tumor therapeutic effects, which is better than the effect of existing immune checkpoint inhibitors in inhibiting tumors. Therefore, IL-33 can be used as a tumor treatment drug, as a tumor immune stimulator to activate the body's immune cells to play a role in treating and preventing tumors, and as a vaccine enhancer to enhance tumor vaccines to prevent the occurrence and development of malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0021] Figure 1 FIG. 4 is a flow chart of tumor infiltrating lymphocyte separation according to an embodiment of the present invention.
[0022] Figure 2 The inhibitory effect of IL-33 of Example 1 of the present invention on B16-F10 melanoma is negatively correlated with the tumor burden.
[0023] Figure 3The effects of IL-33 administration methods and dosages on tumor inhibition in Example 2 of the present invention; (a) Schematic diagram of different IL-33 administration methods; (bd) Effects of different administration methods on tumor growth, except for (d) where the B16-F10 tumor cell inoculation concentration was 1×10 5 The B16-F10 tumor cell inoculation dose in the other groups was 3×10 5 .
[0024] Figure 4 The inhibitory effect of IL-33 of Example 3 of the present invention on B16-F10 melanoma; (ab) FACS analysis of the changes in the proportion of eosinophils in tumor-infiltrating immune cells; (cd) FACS analysis of the changes in the proportion of ILC2 in tumor-infiltrating immune cells; (eg) FACS analysis of the total number of Tregs and ST2 in tumor-infiltrating immune cells + (h) Survival curves of the IL-33-administered group and the PBS control group (n=7), and the p-value of the survival curve was calculated using the Log-rank (Mantel-Cox) test.
[0025] Figure 5 IL-33 of Example 3 of the present invention can significantly increase the number of tumor-infiltrating immune cells; statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (a) CD45 infiltrating tumors in different treatment groups + Changes in the number of immune cells; (b) Myeloid CD11b in different treatment groups + (c) Changes in the number of eosinophils in different treatment groups; (d) Changes in the number of neutrophils in different treatment groups; (e) Changes in the number of ILC2 cells in different treatment groups; (f) Changes in the number of TCRβ in different treatment groups + Changes in the number of T cells; (g) Changes in the number of CD4 T cells in different treatment groups; (h) Changes in the number of CD8 T cells in different treatment groups; (i) Changes in the number of total Treg cells in different treatment groups; (j) ST2 in different treatment groups + Changes in the number of Treg cells.
[0026] Figure 6IL-33 of Example 3 of the present invention can activate CD8 T cell function by promoting the antigen presentation function of ILC2 and exert anti-tumor effect; (a) Gene expression difference analysis of tumor-infiltrating ILC2 cells with or without IL-33; (b) t-SNE shows the clustering results of tumor-infiltrating immune cells; (c and d) tSNE shows the expression distribution of MHC-I related genes H2-Q7 and H2-K1; (e and f) RT-PCR verifies that H2-Q7 and H2-K1 genes are highly expressed in the IL-33 treatment group; (g) GSEA analysis shows that antigen processing and presentation signaling pathways are significantly enriched in ILC2 cells; (h) UMAP shows the clustering of tumor-infiltrating immune cells Results; (i) AUCell analysis of the strength of antigen processing and presentation signaling pathways enriched at the single-cell level; (j) The ability of ILC2 and DC cells to absorb and process DQ-OVA antigen in vitro; (k) Flow cytometry detection of mean fluorescence values indicating the ability of ILC2 cells to absorb and process DQ-OVA antigen in the presence or absence of IL-33; (l) The mean fluorescence values were normalized to the change multiple of MFI, indicating that IL-33 can significantly enhance the ability of ILC2 cells to absorb and process DQ-OVA antigen; (n) The effect of co-incubation of ILC2 and OT-ICD8 T cells under different treatment conditions on the proliferation of CD8 T cells; (m) Statistical analysis of the effect of ILC2 under different treatment conditions on the proliferation of OT-ICD8 T cells; (o) The effect of co-incubation of ILC2 and OT-IICD4 T cells under different treatment conditions on the proliferation of CD4 T cells; (p) Statistical analysis of the effect of ILC2 under different treatment conditions on the proliferation of OT-IICD4 T cells.
[0027] Figure 7 IL-33 of Example 4 of the present invention is 1133 - / - B16-F10 inoculated to Il33 - / - The tumor suppression effect in mice. (a) Western Blot verification of the knockout effect of CRISPR-Cas9 on the Il33 gene in B16-F10; (b) Inoculation of Il33 - / - B16-F10 melanoma cell lines to Il33 - / -Growth curve of mouse tumor (IL-33 experimental group n=11, PBS control group n=10), tumor curve data are expressed as mean±SEM, and other data are expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (c) Comparison of tumor weight between the IL-33-treated group and the PBS control group after tumor detachment; (d) Size of a single tumor after tumor detachment; (e) Survival curves of the IL-33-treated group and the PBS control group (IL-33 experimental group n=7, PBS control group n=6), the p value of the survival curve was calculated using the Log-rank (Mantel-Cox) test; (f) FACS analysis of the changes in the proportion of eosinophils in tumor-infiltrating immune cells; (g) FACS analysis of the changes in the proportion of ILC2 cells in tumor-infiltrating immune cells; (h) FACS analysis of the changes in the proportion of Treg cells in tumor-infiltrating immune cells; (i) FACS analysis of ST2 in tumor-infiltrating immune cells + Changes in the proportion of Treg cells.
[0028] Figure 8 The IL-33 of Example 5 of the present invention is inoculated to B16-F10 until Il1rl1 - / - The tumor suppressor effect in mice; (a) Inoculation of B16-F10 melanoma cell line into Il1rl1 - / - Growth curve of tumors in mice (n=3), tumor curve data are expressed as mean±SEM, and other data are expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Comparison of tumor weight between IL-33 administration group and PBS control group after tumor removal; (c) Size of single tumor after tumor removal; (d) FACS analysis of changes in the proportion of eosinophils in tumor-infiltrating immune cells; (e) FACS analysis of changes in the proportion of ILC2 cells in tumor-infiltrating immune cells; (f) FACS analysis of changes in the proportion of Treg in tumor-infiltrating immune cells.
[0029] Fig. 9The IL-33 of Example 6 of the present invention shows the tumor inhibition effect of B16-F10 inoculated into NSG mice. (a) The growth curve of the tumor after inoculation of B16-F10 melanoma cell line into NSG mice (n=6), the tumor curve data are all expressed as mean±SEM, and the other data are all expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Comparison of tumor weights between the IL-33 administration group and the PBS control group after tumor peeling; (c) The size of a single tumor after tumor peeling; (d) FACS analysis of changes in the proportion of eosinophils in tumor-infiltrating immune cells.
[0030] Fig.10 This is the tumor-suppressing effect of IL-33 of Example 7 of the present invention on MC38 colon cancer. (a) The growth curve of the tumor after inoculation of MC38 colon cancer cell line into C57BL / 6N mice (n=6), the tumor curve data are all expressed as mean±SEM, and the other data are all expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Comparison of tumor weight between the IL-33 administration group and the PBS control group after tumor removal; (c) The size of a single tumor after tumor removal; (d) FACS analysis of changes in the proportion of eosinophils in tumor-infiltrating immune cells; (e) FACS analysis of changes in the proportion of ILC2 in tumor-infiltrating immune cells; (f) FACS analysis of changes in the proportion of Treg cells in tumor-infiltrating immune cells; (g) FACS analysis of ST2 in tumor-infiltrating immune cells + Changes in the proportion of Treg cells.
[0031] Fig.11The IL-33 of Example 7 of the present invention has an inhibitory effect on CT26.WT colon cancer; (a) The growth curve of the tumor after inoculating the CT26.WT mouse colon cancer cell line into BALB / c mice (n=6), the tumor curve data are all expressed as mean±SEM, and the other data are all expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Comparison of tumor weights between the IL-33 administration group and the PBS control group after tumor peeling; (c) The size of a single tumor after tumor peeling; (d) FACS analysis of changes in the proportion of eosinophils in tumor-infiltrating immune cells; (e) FACS analysis of changes in the proportion of ILC2 in tumor-infiltrating immune cells; (f) FACS analysis of changes in the proportion of Treg cells in tumor-infiltrating immune cells; (g) FACS analysis of ST2 in tumor-infiltrating immune cells + Changes in the proportion of Treg cells.
[0032] Fig.12 The tumor suppressive effect of IL-33 on breast cancer in Example 7 of the present invention; (a) The growth curve of the tumor after inoculation of 4T1 breast cancer cell line into BALB / c mice (n=5), the tumor curve data are all expressed as mean±SEM, and the other data are all expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; b) Comparison of tumor weight between the IL-33 administration group and the PBS control group after tumor peeling; c) The size of a single tumor after tumor peeling; d) FACS analysis of the change in the proportion of eosinophils in tumor-infiltrating immune cells; e) FACS analysis of the change in the proportion of ILC2 in tumor-infiltrating immune cells; f) FACS analysis of the change in the proportion of Treg cells in tumor-infiltrating immune cells; g) FACS analysis of ST2 in tumor-infiltrating immune cells + Changes in the proportion of Treg cells.
[0033] Fig.13The IL-33 of Example 7 of the present invention has an inhibitory effect on lung cancer; (a) The growth curve of the tumor after inoculation of Lewis lung cancer cell line into C57BL / 6N mice (n=6), the tumor curve data are all expressed as mean±SEM, and the other data are all expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Comparison of tumor weight between the IL-33 administration group and the PBS control group after tumor peeling; (c) The size of a single tumor after tumor peeling; (d) FACS analysis of the change in the proportion of eosinophils in tumor-infiltrating immune cells; (e) FACS analysis of the change in the proportion of ILC2 in tumor-infiltrating immune cells; (f) FACS analysis of the change in the proportion of Treg cells in tumor-infiltrating immune cells; (g) FACS analysis of ST2 in tumor-infiltrating immune cells + Changes in the proportion of Treg cells.
[0034] Fig.14 Comparison of IL-33 and immune checkpoint antibody blocker treatment in Example 8 of the present invention; (a) Growth curves of tumors after different drugs were given to C57BL / 6N mice after inoculation of B16-F10 melanoma cell line (n=4 or 5 or 6), tumor curve data are all expressed as mean±SEM, and other data are expressed as mean±SD. Statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b) Size of a single tumor after tumor peeling; (c) Comparison of tumor weights of each drug-treated group and the control group after tumor peeling; (d) FACS analysis of ST2 in tumor-infiltrating immune cells + (e) FACS analysis of changes in the proportion of ILC2 in tumor-infiltrating immune cells.
[0035] Fig.15 The IL-33 of Example 9 of the present invention can enhance the effect of preventive tumor vaccine; (a) vaccination process; (b) further vaccination with 5×10 5Tumor growth curve after CT26.WT live cells, where PBS and rmIL-33 groups were unvaccinated groups, but were intraperitoneally injected with PBS and 1μg / mouse / day IL-33, respectively, and PBS Vaccine and rmIL-33 Vaccine were vaccinated groups, and were intraperitoneally injected with PBS and 1μg / mouse / day IL-33, respectively, at the same time as the irradiated whole cell vaccine. (c) Overall survival curve of mice in each treatment group; (d) Tumor normal curve of IL-33 enhancing the anti-tumor effect of B16-F10 vaccine; (e) Tumor size of different treatment groups; (f) Overall survival curve of mice in each treatment group. DETAILED DESCRIPTION
[0036] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work should fall within the scope of protection of the present invention.
[0037] The present invention starts from the perspective of IL-33 regulating tumor immune cells and examines its effect on tumor-infiltrating immune cells to improve the inhibitory tumor immune microenvironment and promote tumor immunity. The results show that IL-33 can increase the number and proportion of tumor-infiltrating immune cells expressing ST2, such as: ST2 + Treg, ILC2 and eosinophils can significantly inhibit the growth of mouse tumors including MC38, CT26.WT, Lewis, 4T1 and B16-F10.
[0038] The basic content of the technical solution of the present invention is as follows: B16-F10 melanoma cells, Lewis lung cancer cell line, MC38 or CT26.WT colon cancer cell line and breast cancer cell line 4T1 are subcutaneously inoculated into the right abdomen and back of the mice, and the mice are intraperitoneally injected with a corresponding dose of recombinant IL-33 before, at the same time as or when a visible tumor grows (see the specific process for details). Figure 3 a) The length and width of the tumor were measured with a vernier caliper from the fifth to seventh day after the mice were inoculated with the tumor. The size of the tumor was calculated by the formula: Tumor volume = length × width 2 / 2. When the tumor size of any mouse in the experimental group approaches 1000mm 3Or when the diameter is greater than 15mm, all mice were killed by cervical dislocation and the tumors were removed. The tumors were photographed, recorded and weighed, and then cut into pieces with scissors. Then, different volumes of 1mg / ml collagenase IV and 0.25mg / ml DNaseI were added according to the size of the tumor. The specific amount added is shown in Table 1. Digestion was carried out on a shaker at 37℃ and 10rpm for 30-45min. The digested samples were ground and filtered through a 70μm cell sieve to form a single cell suspension, and centrifuged at 400×g for 5min. The supernatant was discarded as much as possible, and 3ml of ACK lysis buffer was added to each tumor for lysis at room temperature and in the dark for 3min, and then 5-10 times PBS was added and centrifuged at 400×g for 5min.
[0039] Table 1 Tumor weight and digestive fluid volume required
[0040]
[0041] After centrifugation, discard the supernatant as much as possible, and add the same volume of 40% percoll solution as the digestion solution to each tumor sample to resuspend the cells. Slowly add each 5ml tumor cell suspension to a tilted sterile 15ml centrifuge tube containing 5ml 80% percoll in each tube, set the acceleration rate to 1, the deceleration rate to 0, and centrifuge at 900×g and 24℃ for 25min. Carefully aspirate the middle layer of white film into a new centrifuge tube, add 5 to 10 times the volume of PBS, and centrifuge at 400×g for 10min. For the specific operation process, see Figure 1 .
[0042] After the above cell suspension was centrifuged and the supernatant was discarded, the cells obtained after removing the red blood cells were resuspended with 3ml PBS and added to a 5ml flow tube, and centrifuged at 400×g and 4℃ for 5min. The supernatant was discarded as much as possible, and 100μl flow staining solution and 1:50 anti-CD16 / CD32 antibody and 1:500 diluted Zombie-NIR were added to each tube and incubated at 4℃ for 15min. Each sample was divided into two tubes, each with 50μl cell suspension, and then 50μl of the fluorescent labeled antibody mixture shown in Table 2 was added respectively, incubated at 4℃ for 45min, and then washed three times with PBS solution containing 0.3% BSA and detected with BD AriaIII.
[0043] Table 2 Flow cytometry fluorescent antibody staining protocol
[0044]
[0045] According to the above color scheme, the classification of each cell population is defined as follows: ILC2 is Zombie - CD45 + Lineage - (TCRβ - CD11b- CD11c - Gr1 - B220 - FcεRI - CD335 - )CD90.2 + CD127 + KLRG1 + ST2 + ; Eosinophils are zombies - CD45 + CD11b + Ly-6G - Siglec + ; Neutrophils are Zombies - CD45 + CD11b + Siglec - Ly-6G + ; T cells are zombies - CD45 + TCRβ + ; CD4 T cells are zombies - CD45 + TCRβ + CD4 + ;CD8 T cells are zombies - CD45 + TCRβ + CD8 + ; Treg cells are zombies - CD45 + TCRβ + CD4 + Foxp3 + Flowjo software was used to analyze the changes in various populations of tumor-infiltrating lymphocytes with and without drug administration.
[0046] Example 1 The tumor-suppressing effect of IL-33 is negatively correlated with the tumor burden
[0047] Different amounts of tumor cells were inoculated to investigate the inhibitory effect of IL-33 on tumors. Figure 2 (a) is inoculated with 5×10 5 The growth curve of the tumor after inoculation of 3×10 5The growth curves of the B16-F10 melanoma cell line after inoculation (n = 5 or 6). Except for the tumor curve, all other data are expressed as mean ± SEM. (f) The tumor was inoculated with 1×10 5 The growth curve of the tumor after B16-F10 melanoma cell line (n=6), statistical analysis was performed using student's t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (b, d and g) are the comparisons of tumor weights between the IL-33 administration group and the PBS control group after tumor removal; (c, e and h) are the sizes of individual tumors after tumor removal. The results show that when the tumor load is larger, the inhibitory effect of IL-33 on tumors is weaker.
[0048] Example 2 Effect of IL-33 administration method on its tumor inhibition
[0049] By designing different experimental conditions to investigate the administration conditions and dosage of IL-33 ( Figure 3 a) The results showed that IL-33 administration 2 days in advance at 1 μg per day (A) or 0.5 μg per day (B), intermittent administration 1 day in advance (C), simultaneous administration (D) or administration when visible tumors grow (E) can effectively inhibit tumor growth ( Figure 3 bd).
[0050] Example 3 IL-33 can significantly increase the number of tumor-infiltrating immune cells and affect the proportion of various types of tumor-infiltrating immune cells
[0051] Preliminary results have shown that IL-33 can significantly inhibit the growth of melanoma ( Figure 2 and Figure 3 ), the tumor weight was significantly lower than that of the control group ( Figure 2 ). When further analysis of tumor-infiltrating cells was performed, it was found that the proportion of tumor-infiltrating eosinophils increased significantly ( Figure 4 a and 4b), the proportion of ILC2 cells increased significantly ( Figure 4 c and 4d), when the total number of Treg cells remained unchanged ( Figure 4 e and 4f), ST2 + The proportion of Treg cells also increased ( Figure 4 g). The IL-33 administration group can significantly increase the total survival time of mice ( Figure 4 h). We further calculated the number of immune cells infiltrating per gram of tumor ( Figure 5 ), the results showed that IL-33 can significantly increase the number of tumor-infiltrating immune cells ( Figure 5 a), and the total number of myeloid lineages ( Figure 5 b) and eosinophil counts increased significantly ( Figure 5 c). There was no significant change in the number of neutrophils ( Figure 5 d). The number of ILC2 cells also increased significantly ( Figure 5 e). And the number of total tumor-infiltrating T cells ( Figure 5 f) and CD4 T ( Figure 5 g) cells and CD8 T ( Figure 5 h) The number of cells also increased significantly, Treg ( Figure 5 i) and ST2 + Treg( Figure 5 j) also increased significantly. In summary, IL-33 can significantly inhibit tumor growth and change the proportion and number of tumor-infiltrating immune cells, thereby improving the tumor microenvironment.
[0052] In order to find out the mechanism of IL-33 regulating ILC2 to exert anti-tumor function, this example used flow cytometry to sort all tumor-infiltrating immune cells except T cells and B cells, and performed single-cell transcriptomic analysis using 10×Genomics technology. The results showed that the expression of MHC-I related genes such as H2-K1, H2-Q7, B2m, Hspa1a and Hspa1b in ILC2 cells in the IL-33 treatment group increased, while in the PBS control group, the expression of H2-Aa, H2-Ab1, and Cd74 genes was upregulated ( Figure 6 ad). Further Q-PCR verification showed that MHC-I related genes such as H2-Q7 and H2-K1 were also highly expressed in IL-33 treated immune cells ( Figure 6 ef). Through GSEA signaling pathway enrichment analysis, the results showed that ILC2 can enrich antigen processing and presentation signaling pathways ( Figure 6 g). The enrichment of this signaling pathway in each cell was further evaluated using the AUCell R package. The results showed that the enrichment level of the antigen processing and presentation signaling pathway gene set in ILC2 was second only to that of professional APC-DC cells ( Figure 6 hi). To preliminarily verify the antigen processing and handling ability of ILC2, ILC2 and DC cells were sorted and co-incubated with DQ-OVA antigen respectively. The intensity of fluorescent protein released after DQ-OVA was cleaved into peptides in the cell was used to evaluate and detect its ability to absorb and handle exogenous antigens. The results showed that ILC2 cells can process and handle DQ-OVA protein well, although this ability is weaker than that of DC cells ( Figure 6 j). When analyzing the effect of IL-33 on ILC2 absorption and processing of OVA exogenous protein, it was found that IL-33 can significantly enhance the ability of ILC2 to absorb and process OVA protein ( Figure 6kl). By co-incubating ILC2 loaded with OVA protein with OT-I derived CD8 T cells and OT-II derived CD4 T cells, the results showed that OVA-ILC2 could significantly promote the proliferation of OT-I CD8 T and OT-II CD4 T cells ( Figure 6 np), and IL-33 can significantly promote the antigen presentation function of ILC2. In summary, IL-33 can activate T cell function by promoting the antigen presentation function of ILC2 and exert anti-tumor effects.
[0053] Example 4 The inhibitory effect of IL-33 on tumors is not related to the endogenous expression of IL-33 in mice
[0054] Studies have shown that IL-33 expressed by tumors themselves can recruit eosinophils into tumors by increasing intratumoral CCL11, thereby inhibiting tumor development. In order to exclude the effect of IL-33 expressed intrinsically by tumor cells on tumors, this example uses CRISPR-Cas9 technology to knock out IL-33 expressed intrinsically in melanoma cell lines ( Figure 7 a), and inoculated it into Il33 - / - The inhibitory effect of exogenous IL-33 on melanoma was investigated in knockout mice. The results showed that IL-33 could significantly inhibit the growth of melanoma and prolong the overall survival time of mice in the drug-treated group without the presence of endogenous IL-33. Figure 7 be), improve the tumor immune microenvironment, and significantly increase the infiltration of eosinophils and ILC2 in tumors ( Figure 7 fi), the results showed that the inhibitory effect of IL-33 on melanoma was independent of the intrinsic expression of IL33 in the tumor.
[0055] Example 5 The inhibitory effect of IL-33 on tumors is mediated by ST2 receptor
[0056] ST2 is the only receptor for IL-33. To verify that the effect of IL-33 can only be regulated by ST2, this project further identified Il1rl1 - / - The results showed that when B16-F10 was inoculated into Il1rl1 - / - In mice, IL-33 was unable to inhibit tumor growth ( Figure 8 ac), and there was no significant change in tumor-infiltrating immune cells ILC2 and eosinophils ( Figure 8 dg). Based on this, it can be inferred that the inhibitory effect of IL-33 on tumors is mainly achieved through the regulation of the receptor ST2 on immune cells. When the body's immune cells lack the ST2 receptor, the inhibitory effect of IL-33 on tumors disappears.
[0057] Example 6 The inhibitory effect of IL-33 on tumors requires the participation of lymphocytes
[0058] Existing studies and previous research results have shown that the inhibitory effect of IL-33 on tumors is mainly caused by changes in the tumor microenvironment caused by ILC2 and eosinophil tumor infiltration, thereby exerting an anti-tumor effect. The results of the combined and separate anti-tumor effects of the two have been reported. In order to verify the role of eosinophils themselves in anti-tumor, this example inoculated B16-F10 into lymphocyte-deficient NSG mice to examine the inhibitory effect of IL-33 on tumors in the absence of ILC2. The results showed that when ILC2 and T / B cells were missing, IL-33 could not inhibit tumor growth ( Fig. 9 ac), and eosinophils can only increase slightly under the action of IL-33 ( Fig. 9 d). Although continuous stimulation of IL-33 can significantly increase the proportion of eosinophils in tumor-infiltrating immune cells, the increase rate is much lower than that of the normal mouse administration group, and it cannot inhibit tumor growth, indicating that IL-33 has a weak effect on the in situ proliferation of tumor-infiltrating eosinophils, and its tumor infiltration depends largely on the recruitment of tumor-infiltrating ILC2 to the tumor microenvironment. Therefore, the inhibitory effect of IL-33 on tumors depends largely on ILC2 infiltrating into the tumor and recruiting eosinophils, thereby improving the tumor microenvironment to exert anti-tumor effects.
[0059] Example 7 Applicability Study of IL-33
[0060] To further verify that the anti-tumor effect of IL-33 is applicable to other solid tumors, in this example, MC38 and CT26.WT colon cancer cell lines and Lewis lung cancer cell line were subcutaneously inoculated into their corresponding WT mice, and IL-33 was continuously administered for treatment. The results showed that IL-33 can also inhibit colon cancer ( Fig.10 and 11 ), breast cancer( Fig.12 ) and lung cancer ( Fig.13 ) and also increased tumor-infiltrating immune cells ILC2, eosinophils, and ST2 + The proportion of Tregs can synergistically exert anti-tumor effects.
[0061] Example 8 IL-33 can significantly inhibit tumors, and its inhibitory effect is better than PD-1 and CTLA-4 antibody treatment
[0062] To further demonstrate the anti-tumor effect of IL-33, this example compares the effects of IL-33 and two existing immune checkpoint blockade therapeutic antibodies. Figure 3aA was administered intraperitoneally at 1 μg / mouse / day for 12 consecutive days, and αPD-1 and αCTLA-4 were injected intraperitoneally at 200 μg per mouse on the 5th and 8th days, respectively. Fig.14 As shown, IL-33 can significantly inhibit tumor growth ( Fig.14 ac), and its inhibitory effect was slightly better than the two existing immune checkpoint antibodies. Further analysis of tumor-infiltrating immune cells showed that the effect of IL-33 on the tumor microenvironment was significantly different from that of the two blocking antibodies. IL-33 could significantly increase ST2 + Treg( Fig.14 d) and ILC2 cells ( Fig.14 e), further proving that IL-33 regulates the tumor immune microenvironment by acting on immune cells expressing ST2 to achieve the effect of tumor inhibition.
[0063] Example 9 IL-33 can enhance the effect of preventive tumor vaccines
[0064] To further demonstrate the tumor prevention effect of IL-33, this example used 40 Gy of X-ray irradiation to CT26.WT tumor cells as a vaccine, with 1×10 6 The inoculation volume of cells / mouse was once subcutaneously inoculated into BALB / c mice ( Fig.15 a), and then randomly divided into 2 groups, one group was injected with PBS, and the other group was intraperitoneally injected with 1 μg / mouse / day of IL-33 for 7 consecutive days; a non-vaccine control group was set up, and the mice were randomly divided into PBS and IL-33 groups. Each group had 5 to 6 mice. After 6 weeks of drug withdrawal, 5×10 5 Living cells / mouse, the tumor size was measured and recorded every two days after the growth of visible tumors. The results showed that IL-33 itself has no possibility of preventing tumors, but IL-33 can significantly enhance the anti-tumor effect of vaccines ( Fig.15 b) and prolonged the overall survival time of mice ( Fig.15 c) To further verify the effect of IL-33 on tumor vaccines, we inoculated 3×10 5 B16-F10 vaccine was administered to C57BL / 6N mice, and then randomly divided into 2 groups. One group was injected with PBS, and the other group was intraperitoneally injected with 1 μg / mouse / day of IL-33 for 7 consecutive days. After 6 weeks of withdrawal, 1×10 5 Live cells / mouse, tumor size was measured and recorded every two days after visible tumors grew. The results showed that IL-33 can also significantly enhance the anti-tumor effect of the vaccine ( Fig.15 d and e), prolonging the overall survival time of mice ( Fig.15f). In summary, IL-33 can enhance the effect of tumor vaccines, so IL-33 can be used as an immune activator or vaccine enhancer, and the vaccine includes but is not limited to mRNA vaccines, DC vaccines, and dead cell vaccines.
[0065] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of IL-33 in the preparation of drugs for regulating the proportion and / or number of ILC2 cells.
2. The use according to claim 1, characterized in that: The proportion and / or number of ILC2 cells increases.
3. The use according to claim 1, characterized in that: The dosage of IL-33 is 0.5-1 μg / mouse / day, preferably 0.5 μg / mouse / day or 1 μg / mouse / day.
4. The use according to claim 1, characterized in that: The IL-33 is administered daily 2 days in advance, intermittently 1 day in advance, simultaneously, or when a tumor visible to the naked eye grows.
5. The use according to claim 1, characterized in that: IL-33 acts synergistically by promoting the antigen presentation function of ILC2 cells to activate T cells and increase the tumor infiltration of ST2-expressing immune cells.
6. The use according to claim 1, characterized in that: The drug is an immune activator or a vaccine enhancer, and the vaccine is any one of an mRNA vaccine, a DC vaccine, and a dead cell vaccine.
7. Use of IL-33 in the preparation of a drug for treating cancer, characterized in that: The cancer is any one of colon cancer, breast cancer, lung cancer and melanoma.
8. Use of IL-33 in the preparation of a medicament for enhancing the preventive and / or anti-tumor effects of tumor vaccines.
9. The use according to claim 8, characterized in that: The tumor vaccine is any one of mRNA vaccine, DC vaccine or dead cell vaccine.
10. The use according to any one of claims 7 to 9, characterized in that: The drug increases the proportion and / or number of ILC2 cells.
11. The use according to any one of claims 8 to 10, characterized in that: The tumor is any one of colon cancer, breast cancer, lung cancer and melanoma.
Citation Information
Patent Citations
Methods of treating cancer using IL-33 proteins
CN114555109A
Il-33 secreting immunoresponsive cells and uses thereof
US20200399598A1
